3+PRN

DRUG2 trials

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Zhongshan Ophthalmic Center, Sun Yat-sen University

Conditions

Myopic Choroidal NeovascularisationNeovascular Age-related Macular Degeneration

Phase 4

Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNeovascular Age-related Macular Degeneration

Start: 2013-12-31End: 2017-01-31Target: 115Updated: 2016-11-04

Unknown Phase

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

CompletedNCT03971162

Zhongshan Ophthalmic Center, Sun Yat-sen UniversityMyopic Choroidal Neovascularisation

Start: 2019-06-13End: 2023-01-01Updated: 2023-03-30

Related Papers

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Journal of Ophthalmology2019-10-1014 citations